Format

Send to

Choose Destination
ERJ Open Res. 2018 Nov 20;4(4). pii: 00050-2018. doi: 10.1183/23120541.00050-2018. eCollection 2018 Oct.

The Swiss Paediatric Airway Cohort (SPAC).

Author information

1
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
2
These authors contributed equally.
3
Division of Paediatric Pulmonology, Children's Hospital, St Gallen, Switzerland.
4
Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Bern, Switzerland.
5
Dept of Paediatrics, University Children's Hospital, University of Basel, Basel, Switzerland.
6
Division of Paediatric Pulmonology, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
7
Division of Paediatric Pulmonology, Children's Hospital, Lucerne, Switzerland.
8
Paediatric Practice, Worb, Switzerland.

Abstract

Chronic respiratory symptoms, such as cough, wheeze and dyspnoea, are common in children; however, most research has, with the exception of a few large-scale clinical cohort studies, been performed in the general population or in small, highly-selected samples. The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and adolescents who visit physicians for recurrent conditions, such as wheeze and cough, and exercise-related respiratory problems. The SPAC is an observational study and baseline assessment includes standardised questionnaires for families and data extracted from hospital records, including results of clinically indicated investigations, diagnoses and treatments. Outcomes are assessed through annual questionnaires, monthly symptom reporting via mobile phone and follow-up visits. The SPAC will address important questions about clinical phenotypes, diagnosis, treatment, and the short- and long-term prognosis of common respiratory problems in children. The cohort currently consists of 347 patients from four major hospitals (Bern, Zurich, Basel and Lucerne), with 70-80 additional patients joining each month. More centres will join and the target sample size is a minimum of 3000 patients. The SPAC will provide real-life data on children visiting the Swiss healthcare system for common respiratory problems and will provide a research platform for health services research and nested clinical and translational studies.

Conflict of interest statement

Conflict of interest: P. Latzin reports receiving personal fees from Gilead, Novartis, Roche, Schwabe, Vertex, Vifor and Zambon outside the submitted work.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center